Real-World Studies
Medication-Related Problems in Critically Ill Oncology Patients
Abraham et alJournal of Oncology Pharmacy Practice

In a prospective observational study conducted over 14 months in an oncology intensive care unit (ICU) of a tertiary cancer centre, researchers evaluated the prevalence, determinants, and outcomes of medication-related problems (MRPs) along with antimicrobial consumption and clinical pharmacist interventions among 325 adult patients admitted for at least 48 hours. The cohort had a mean age of 54.6 ± 12.3 years and was 58.5% male.
MRPs were categorized using the Pharmaceutical Care Network Europe classification V9.1. Overall, 82.5% of patients (n = 268) experienced at least one MRP, with 612 total events recorded (mean 1.88 per patient). The predominant categories were treatment-effectiveness issues (38.1%) and treatment-safety issues (28.9%). Antimicrobial therapy was administered to 91.1% of patients (n = 296), with consumption totaling 142.6 defined daily doses (DDD) per 100 bed-days; agents in the World Health Organization AWaRe 'Watch' category accounted for 54.2% of this utilization.
Multivariate logistic regression revealed that polypharmacy, prolonged ICU length of stay, renal impairment, hematological malignancy, and the concurrent administration of two or more antimicrobials served as independent predictors of MRP occurrence. Clinical pharmacists initiated 540 interventions, achieving an acceptance rate of 86.3% (n = 466). In clinical outcome evaluations, patients with unresolved or severe MRPs demonstrated significantly higher mortality compared to patients without MRPs (34.2% vs 18.6%, p = 0.002).
Key Takeaways
- Medication-related problems occurred in 82.5% of critically ill oncology patients, and patients with unresolved or severe problems had significantly higher mortality than those without them (34.2% vs 18.6%, p = 0.002).
- Independent predictors of medication-related problem occurrence included polypharmacy, prolonged intensive care stay, renal impairment, hematological malignancy, and concurrent use of two or more antimicrobials.
- Clinical pharmacists implemented 540 interventions with an 86.3% acceptance rate in a setting where 91.1% of patients received antimicrobials, predominantly driven by WHO Watch category agents (54.2%).
Read the original sourceJournal of Oncology Pharmacy Practice
